Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2026 / April / Early Fluid Resolution Predicts Faricimab Durability
Anterior Segment Research & Innovations News

Early Fluid Resolution Predicts Faricimab Durability

Post hoc analysis suggests rapid retinal fluid clearance may help identify nAMD patients who can maintain longer faricimab dosing intervals

4/7/2026 2 min read

Share

  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Top Institutions
Top Institutions in Ophthalmology, Retinal Disease

Leading institutions in ophthalmology and retinal disease research have conducted and contributed to large-scale randomized clinical trials such as TENAYA and LUCERNE, utilizing advanced imaging and clinical outcome measures to evaluate novel therapeutics like faricimab for nAMD.

  • #1

    Bascom Palmer Eye Institute

    Miami, FL

    Bascom Palmer is consistently ranked as a top ophthalmology center with extensive expertise in retinal diseases and leadership in clinical trials for novel therapies in nAMD, including anti-VEGF agents.

    Key Differentiators

    • Ophthalmology
    • Retina
    • Clinical Trials
  • #2

    Massachusetts Eye and Ear Infirmary

    Boston, MA

    Massachusetts Eye and Ear is a leader in translational retinal research and clinical trials, with a strong focus on novel biologics and imaging techniques to optimize treatment strategies for nAMD.

    Key Differentiators

    • Ophthalmology
    • Retina
    • Translational Research
  • #3

    Johns Hopkins Wilmer Eye Institute

    Baltimore, MD

    Wilmer Eye Institute has a strong clinical research program in retinal diseases, with expertise in evaluating new pharmacologic agents and personalized treatment regimens for nAMD.

    Key Differentiators

    • Ophthalmology
    • Retina
    • Clinical Research
  • #4

    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    UCSF is recognized for its innovative retinal disease research and involvement in clinical trials assessing durability and efficacy of novel agents like faricimab in nAMD.

    Key Differentiators

    • Ophthalmology
    • Retina
    • Clinical Trials
  • #5

    Moorfields Eye Hospital

    London, N/A

    Moorfields is a global leader in ophthalmic research and clinical trials, with a strong focus on retinal diseases and novel therapeutic agents for nAMD including faricimab.

    Key Differentiators

    • Ophthalmology
    • Retina
    • Clinical Trials

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: